Predictive Value of Glycemic Parameters Measured With the FSL Pro iQ During ACS

NARecruitingINTERVENTIONAL
Enrollment

850

Participants

Timeline

Start Date

November 6, 2023

Primary Completion Date

May 6, 2028

Study Completion Date

May 6, 2028

Conditions
Acute Coronary SyndromeContinuous Glucose MeasurementGlycemic VariabilityCardiovascular Event
Interventions
DEVICE

Freestyle Libre Pro iQ

"Freestyle Libre Pro iQ is a professional sensor, marketed by the Abbott laboratory, for continuous, non-invasive interstitial glucose measurement allowing the recording of glycemic parameters for 2 weeks.~The study will be offered to any subject with an ACS. The installation of the Freestyle Libre Pro iQ sensor will be performed upon admission to intensive care Cardiology and left in place for the duration of hospitalization. In case of the Freestyle Libre Pro iQ sensor defective or removed before discharge from hospital, and if the patient tolerates it, a new the Freestyle Libre Pro iQ sensor will be placed. If the duration of hospitalization exceeds 14 days, a 2nd sensor will be placed."

Trial Locations (9)

30029

RECRUITING

University Hospital of Nîmes, Nîmes

31059

RECRUITING

University Hospital of Toulouse, Toulouse

33604

RECRUITING

University Hospital of Bordeaux, Bordeaux

34295

RECRUITING

University Hospital of Montpellier, Montpellier

34500

RECRUITING

Hospital of Béziers, Béziers

64046

RECRUITING

Hospital of Pau, Pau

75010

RECRUITING

AP-HP Lariboisière Hospital, Paris

75015

RECRUITING

APHP - Hôpital Européen Georges Pompidou, Paris

Unknown

RECRUITING

Vannes Bretagne Atlantique Hospital, Vannes

All Listed Sponsors
lead

University Hospital, Montpellier

OTHER